dose escalation is the most under-discussed thing on this board
Something I keep coming back to: dose escalation is the most under-discussed thing on this board.
The early fullness profile felt different rather than worse. Hard to describe and impossible to quantify, so take it as an impression.
Watched heart rate on a wearable across twelve weeks because the threads said to. It moved a little and I have no idea whether that means anything.
The thing that surprised me was how much of the discussion here is inference rather than measurement.
That is everything I have. The rest is opinion and I have tried to keep it out.
best — the order this archive was captured in
Standing reminder in every thread here: unapproved compound, research material is not for human use, nothing on this board is medical advice.
Is that the 48-week figure or an earlier readout?
triple agonist — GLP-1, GIP and glucagon, and the glucagon arm is the new part
The standing caveat, written out properly because it keeps getting compressed into a footnote.
Nothing containing this compound is approved by any regulator. Research-use-only material is not approved for human use. That is not a legal formality on this board — it is why there is so little independent data, why the escalation schedules people post are invented, and why nobody here can answer a dosing question.
What this board can usefully do is read the published trials carefully, log independent purity results, and be honest about how thin the evidence base is. Everything else belongs somewhere with a clinician in it.
Increases in heart rate have been reported across this receptor class. The magnitude and clinical significance are exactly what phase 3 is powered to establish.
That is body weight change, not fat mass. The trials report the first and people quote it as the second.
Are you tracking heart rate at all?
the energy-expenditure story is mechanistically interesting and clinically unproven
the phase 2 numbers were striking and they were also 48 weeks in a small population
comparing reta phase 2 to sema phase 3 is comparing different things
heart rate is the thing people report watching
The phase 2 readout ran to 48 weeks in a few hundred participants with a slow escalation. Both the size and the duration matter when people quote the headline number.
phase 2 data only, and people quote it like it is a label
Independent purity testing on this compound is thin compared with the older molecules, simply because fewer members have paid for it. Fewer results means wider uncertainty, not a verdict.
Glucagon receptor agonism is associated with increased energy expenditure and with hepatic effects. That is a mechanistic story with strong preclinical support and limited phase 2 human data.
small trial, big effect, wide error bars
- 1The standing caveat, written out properly because it keeps getting…9 comments in this branch · started by u/crosspost_bot_no